Skip to main content
. 2013 Apr 18;8(6):969–978. doi: 10.2215/CJN.04680512

Table 4.

Changes in relative erythropoietic resistance index and hemoglobin by type of erythropoiesis-stimulating agent from study initiation to study completion

Group Observation Period (mo)
0 1 2 3 4 5 6 7 8 9 10 11 12
Relative ERI (10.0–10.9) rHuEPO
 VPS-HA 1.0 1.0±0.4 1.0±0.6 0.9±0.7 1.0±0.7 1.0±0.8 1.1±0.8 1.0±0.7 1.0±0.7 1.1±0.7 1.4±1.6 1.5±2.2 1.2±1.4
 P (versus 0) — 0.82 0.11 0.06 0.39 0.48 0.74 0.90 0.67 0.69 0.28 0.88 0.62
 PS-con 1.0 1.2±0.9 1.3±0.9 1.2±1.0 1.2±1.2 1.1±1.0 1.1±0.9 1.2±1.0 1.1±1.0 1.4±1.4 1.5±1.5 1.4±1.5 1.2±1.3
 P (versus 0) — 0.64 0.83 0.15 0.02a 0.27 0.13 0.18 0.34 0.39 0.45 0.36 0.20
 P (VPS-HA versus PS-con) — <0.001b <0.001b <0.001b <0.001b <0.01b <0.001b <0.01b <0.01b <0.01b <0.01b <0.01b <0.01b
Hb (g/dl, 10.0–10.9) rHuEPO
 VPS-HA 10.6±0.8 10.6±0.9 10.7±1.0 10.7±0.9 10.7±0.7 10.6±0.7 10.6±0.9 10.5±0.8 10.4±0.8 10.5±0.9 10.6±0.8 10.8±0.8 10.8±0.9
 PS-con 10.7±0.8 10.6±0.9 10.6±1.0 10.8±0.9 10.7±0.8 10.5±0.9 10.5±0.8 10.6±0.8 10.7±0.8 10.6±1.0 10.7±1.0 10.9±1.0 10.9±0.9
Relative ERI (10.0–10.9) DA
 VPS-HA 1.0 1.0±1.3 1.0±0.6 1.0±0.5 1.3±1.1 1.1±0.7 1.0±0.5 1.1±0.7 1.1±0.7 1.2±1.2 0.9±0.6 1.1±0.9 1.1±0.8
 P (versus 0) — 0.38 0.45 0.85 0.36 0.92 0.48 0.82 0.88 0.69 0.20 0.49 0.99
 PS-con 1.0 1.1±0.4 1.1±0.7 1.3±0.7 1.3±0.9 1.2±0.8 1.1±0.8 1.3±0.9 1.2±0.9 1.2±1.0 1.2±1.0 1.2±0.9 1.2±0.9
 P (versus 0) — 0.96 0.75 0.27 0.94 0.75 0.94 0.26 0.48 0.59 0.49 0.35 0.39
 P (VPS-HA versus PS-con) — <0.001b <0.001b <0.001b <0.001b <0.001b <0.001b <0.001b <0.001b <0.001b <0.001b <0.001b <0.001b
Hb (g/dl, 10.0–10.9) DA
 VPS-HA 10.8±0.8 10.7±0.7 10.7±0.6 10.5±0.8 10.4±0.7 10.5±0.6 10.6±0.8 10.4±0.7 10.4±0.9 10.6±0.9 10.7±0.8 10.5±1.0 10.3±0.7
 PS-con 10.7±0.8 10.7±0.7 10.5±0.9 10.6±0.9 10.8±1.1 10.8±0.8 10.7±1.1 10.6±0.8 10.5±1.2 10.6±1.1 10.6±0.9 10.6±1.0 10.4±0.8
Relative ERI (11.0–11.9) rHuEPO
 VPS-HA 1.0 1.2±0.6 1.3±0.8 1.2±0.8 1.4±1.3 1.1±0.8 1.1±0.6 1.4±0.7 1.4±0.8 1.5±1.0 1.5±0.9 1.3±0.9 1.4±0.9
 P (versus 0) — 0.11 0.20 0.72 0.72 0.67 0.73 0.13 0.13 0.04a 0.19 0.51 0.29
 PS-con 1.0 1.0±0.3 1.0±0.9 0.9±0.9 1.1±0.8 1.5±0.8 1.4±0.9 1.4±0.9 1.3±0.8 1.3±0.9 1.6±0.9 1.5±1.3 1.3±0.7
 P (versus 0) — 0.82 0.30 0.21 0.78 0.13 0.23 0.14 0.30 0.40 0.05 0.31 0.43
 P (VPS-HA versus PS-con) — <0.001b <0.01b 0.16 <0.05a <0.01b <0.05a <0.01b <0.01b <0.05a <0.01b <0.01b <0.001b
Hb (g/dl, 11.0–11.9) rHuEPO
 VPS-HA 11.1±1.0 11.3±1.0 11.3±1.2 11.5±0.9 11.4±0.7 11.3±0.7 11.1±0.7 10.9±0.8 11.1±0.9 11.0±0.8 11.2±0.6 11.3±0.9 11.2±1.2
 PS-con 11.0±1.0 10.9±0.9 11.0±1.2 11.3±1.0 10.8±0.7 10.6±0.7 10.5±0.9 10.6±0.8 10.9±0.9 11.1±1.0 11.0±0.9 11.2±0.8 11.1±0.8
Relative ERI (11.0–11.9) DA
 VPS-HA 1.0 0.9±0.2 0.8±0.4 1.0±0.5 0.9±0.5 0.9±0.5 0.9±0.3 0.9±0.4 0.7±0.3 0.7±0.3 0.8±0.3 0.6±0.3 0.7±0.3
 P (versus 0) — 0.65 0.16 0.49 0.10 0.16 0.23 0.22 0.02a <0.001b 0.04a <0.001b <0.001b
 PS-con 1.0 1.3±0.5 1.2±0.8 1.4±0.9 1.3±0.9 1.9±0.9 1.5±1.0 1.3±0.9 1.5±0.8 1.4±1.0 1.5±0.9 1.8±0.8 1.4±1.0
 P (versus 0) — 0.43 0.43 0.11 0.10 <0.01b 0.03a 0.48 0.12 0.08 0.06 <0.001b 0.16
 P (VPS-HA versus PS-con) — <0.001b <0.01b <0.01b <0.001b <0.001b <0.001b <0.01b <0.01b <0.01b <0.01b <0.001b <0.01b
Hb (g/dl, 11.0–11.9) DA
 VPS-HA 11.3±0.9 11.1±0.6 11.2±0.6 11.2±0.7 11.3±0.9 11.0±0.8 11.1±0.8 11.1±0.9 11.3±0.8 11.2±1.0 11.0±0.8 11.0±0.8 11.0±0.9
 PS-con 11.2±0.9 11.0±1.0 11.1±0.8 11.0±0.7 11.3±0.9 11.6±1.0 11.5±1.1 11.4±1.6 11.0±1.7 11.2±1.2 10.9±1.0 11.1±0.7 11.4±0.8

Each patient was allocated to target hemoglobin range depending on one's prestudy level of hemoglobin measured for 3 months, and the target hemoglobin level was kept during this trial. Erythropoietic resistance index (ERI) was calculated by dividing total weekly dose of erythropoiesis stimulating-agent (rHuEPO or DA) by hemoglobin level. ERI is expressed as a ratio relative to the baseline level (time 0). Values are mean ± SD. Statistical testing between the VPS-HA and PS-con groups was performed using the Mann–Whitney U test. Statistical testing was performed using repeated measures analysis of covariance followed by Scheffé posthoc test. When there were significant differences between groups, the data of the group with lower ERI were underlined. VPS-HA, vitamin E-bonded high-flux polysulfone dialysis membrane; rHuEPO, human recombinant erythropoietin; PS-con, type 4 polysulfone dialysis membrane; DA, darbepoetin alfa; 10.0–10.9, target hemoglobin range from 10.0 to 10.9 g/dl; 11.0–11.9, target hemoglobin range from 11.0 to 11.9 g/dl.

a

P<0.05.

b

P<0.01.